Nevertheless, targeting MD-2 to interfere with MD-2–TLR4 signaling has been extensively explored, and the results support the concept that MD-2 is an effective target to treat inflammatory disorders such as sepsis and acute lung injury (53, 65–68). Here, LY96 is linked to Sepsis.